Capricor Therapeutics, Inc. (CAPR) Formed a Wedge Down, Could Be One of The Worst Performers Going Forward

September 8, 2018 - By Victoria Pittman

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Logo

Investors sentiment decreased to 0.44 in Q1 2018. Its down 3.89, from 4.33 in 2017Q4. It worsened, as 4 investors sold Capricor Therapeutics, Inc. shares while 5 reduced holdings. 3 funds opened positions while 1 raised stakes. 1.04 million shares or 76.59% less from 4.44 million shares in 2017Q4 were reported.
Morgan Stanley reported 2 shares stake. Cordasco Financial Ntwk holds 3,100 shares. Royal Bank Of Canada holds 0% or 232 shares. Deutsche Bancorporation Ag holds 0% or 600 shares. Apriem invested in 0.02% or 50,000 shares. Acadian Asset Limited holds 0% of its portfolio in Capricor Therapeutics, Inc. (NASDAQ:CAPR) for 60,753 shares. Northern Corp has 38,660 shares for 0% of their portfolio. Geode Cap Management Ltd Liability accumulated 0% or 76,996 shares. Architects Inc owns 2,000 shares. Blackrock stated it has 0% of its portfolio in Capricor Therapeutics, Inc. (NASDAQ:CAPR). Bankshares Of Mellon invested in 0% or 26,762 shares. Vanguard Group has invested 0% in Capricor Therapeutics, Inc. (NASDAQ:CAPR). Virtu Fincl Ltd Liability Corporation reported 52,410 shares. Perceptive Advisors Ltd Liability holds 4,000 shares or 0% of its portfolio. Commercial Bank Of America Corporation De, North Carolina-based fund reported 5,500 shares.

The stock of Capricor Therapeutics, Inc. (CAPR) formed a down wedge with $1.08 target or 5.00 % below today’s $1.14 share price. The 7 months wedge indicates high risk for the $35.05M company. If the $1.08 price target is reached, the company will be worth $1.75M less.
Falling wedges are poor performers for bullish breakouts and are tricky moments to trade. Investors must be aware that the break even failure rate for up or down breakouts is: 11% and 15%. The average rise is 32% and the decline is 15%. The falling wedges has high throwback and pullback rate: 56%, 69% and the percent of wedges meeting target is not very high.

The stock decreased 0.87% or $0.01 during the last trading session, reaching $1.14. About 84,941 shares traded. Capricor Therapeutics, Inc. (NASDAQ:CAPR) has risen 61.45% since September 8, 2017 and is uptrending. It has outperformed by 48.88% the S&P500.

Analysts await Capricor Therapeutics, Inc. (NASDAQ:CAPR) to report earnings on November, 14. They expect $-0.13 earnings per share, down 8.33 % or $0.01 from last year’s $-0.12 per share. After $-0.14 actual earnings per share reported by Capricor Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -7.14 % EPS growth.

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Ratings Coverage

Among 2 analysts covering Capricor Therapeutics (NASDAQ:CAPR), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Capricor Therapeutics had 3 analyst reports since March 29, 2018 according to SRatingsIntel. H.C. Wainwright maintained the stock with “Buy” rating in Thursday, March 29 report. The firm has “Buy” rating by H.C. Wainwright given on Friday, May 11.

More important recent Capricor Therapeutics, Inc. (NASDAQ:CAPR) news were published by: which released: “Pfizer bails on DMD candidate domagrozumab” on August 30, 2018, also published article titled: “Capricor Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update”, published: “New Research Coverage Highlights Live Nation Entertainment, LightPath Technologies, Synchronoss Technologies …” on August 23, 2018. More interesting news about Capricor Therapeutics, Inc. (NASDAQ:CAPR) was released by: and their article: “Capricor Therapeutics Presents Results of Studies of CAP-2003 at Gordon Research Conference on Extracellular …” with publication date: August 21, 2018.

Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel therapeutics primarily for the treatment of cardiovascular diseases. The company has market cap of $35.05 million. The company's development stage drug candidates for cardiovascular diseases include CAP-1002 that is in Phase II clinical trials; and CAP-2003, which is in pre-clinical development for the treatment of certain cardiac and inflammatory conditions. It has a 19.32 P/E ratio.

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.